Ranbaxy Arm Gets Fda Nod For Midazolam Syrup

Ranbaxy Pharmaceuticals (RPI), a fully owned subsidiary of Ranbaxy Laboratories Ltd in the US, today announced that it has received final approval from the US FDA (US Food and Drug Administration) to market midazolam hydrochloride syrup 3 mg (base)/ml. The molecule recorded sales of $110 million in 2001, sources said.

The approval has been granted to RPI prior to the expiry of the new dosage form exclusivity that was in effect until April 15, 2002.